NASDAQ: YI111 Inc Stock
$1.23+0.00 (+0%)
Updated May 30, 2024
YI Price
$1.23
Fair Value Price
N/A
Market Cap
$105.19M
52 Week Low
$0.97
52 Week High
$3.36
P/E
N/A
P/B
-1.31x
P/S
0.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.04B
Earnings
-$52.04M
Gross Margin
5.6%
Operating Margin
-2.37%
Profit Margin
-2.5%
Debt to Equity
-4.56
Operating Cash Flow
N/A
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
YI Overview
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Zen Score
–
Industry Average (17)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how YI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YI's profit margin has decreased (-0.1%) in the last year from (-2.4%) to (-2.5%)
Profit Margin Growth Financials
YI's short-term assets ($385.27M) exceed its short-term liabilities ($357.45M)
Short-term Liabilities Financials
YI's short-term assets ($385.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more YI due diligence checks available for Premium users.
Be the first to know about important YI news, forecast changes, insider trades & much more!
YI News
Valuation
YI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-2.4x
Market
29.76x
YI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.31x
Industry
1x
YI's financial health
Profit margin
Revenue
$490.1M
Net Income
-$1.9M
Profit Margin
-0.4%
YI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$406.2M
Liabilities
$367.4M
Debt to equity
-4.56
YI's short-term assets ($385.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YI's short-term assets ($385.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
YI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.1M
Investing
$4.1M
Financing
-$21.6M
YI vs Pharmaceutical Retailer Stocks
111 Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.